Astellas Strengthens Neurological Gene Therapy with Sangamo $20M Deal on STAC-BBB
Astellas has made a strategic investment by partnering with Sangamo Therapeutics, contributing $20 million upfront to enhance their neurological gene therapy capabilities[1][2]. This alliance grants Astellas a global license to Sangamo's STAC-BBB, an innovative neurotropic AAV capsid designed to penetrate the blood-brain barrier, thereby potentially advancing genomic medicine delivery for neurological conditions[1][2]. The agreement allows Astellas to potentially explore additional neurological targets, which could lead to further financial incentives for Sangamo in terms of milestone payments and royalties[1].
References
- Astellas pays Sangamo $20M upfront to improve neurological gene therapy capabilities
- <a href="https://www.fiercebiotech.com/biotech/astellas-pays-sangamo-20m-upfront-improve-neurological-gene-therapy-capabilities" hreflang="en">Astellas pays Sangamo $20M upfront to improve neurological gene therapy capabilities</a>
Explore Further
What specific neurological targets does Astellas plan to explore using STAC-BBB technology in its collaboration with Sangamo?
How will the STAC-BBB technology developed by Sangamo improve the delivery of neurological gene therapies?
What challenges did Sangamo face prior to this partnership with Astellas, and how might this deal help overcome them?
What other partnerships or acquisitions has Astellas pursued recently to enhance its gene therapy portfolio?
How does the proven ability of STAC-BBB to penetrate the blood-brain barrier differentiate it from other neurotropic AAV capsids in development?